Polygenic Risk Scores (PRS) Explained: When Thousands of SNPs Add Up to One Risk Estimate

Key Takeaways in 1 Minute

• A Polygenic Risk Score (PRS) combines the effect of hundreds to millions of genetic positions (SNPs) into a single number reflecting your relative likelihood of developing a particular condition.
• Common complex diseases such as type 2 diabetes, heart disease, and many cancers are not caused by one gene, but by many SNPs each contributing a tiny effect.
• A PRS is a statistical probability, not a diagnosis. A high score does not mean you will definitely get the disease.
• The biggest limitation is population bias: most source data come from people of European ancestry, so accuracy drops for Asian and other populations.
• Its real value is to complement risk assessment alongside family history and lifestyle, not to replace medical evaluation.

Hello, I am Dr. Kaet. In my genetics and preventive-medicine practice, one of the most common questions I hear is: "If my DNA test says my cancer risk is high, does that mean I will definitely get cancer?" The short answer is no, and the heart of this misunderstanding lies in something called the Polygenic Risk Score. In this article I will explain how it works, what it is genuinely useful for, and the limitations we must keep in mind before reading too much into it.

How a PRS Works: From Thousands of SNPs to One Number

Our DNA contains positions that vary slightly between individuals, called SNPs (Single Nucleotide Polymorphisms) — a change in a single DNA base. Each of us carries millions of SNPs across the genome. For single-gene disorders (such as some forms of thalassemia), one mutation may explain almost the entire condition. But common chronic diseases like diabetes, heart disease, high blood pressure, and many cancers are polygenic — driven by many SNPs, each nudging risk up or down by only a fraction.

A PRS solves this by adding those effects up systematically. In broad terms, the steps are:

1. Start with large studies called Genome-Wide Association Studies (GWAS), which compare the genomes of hundreds of thousands to millions of people with and without a disease to find which SNPs are associated with it.
2. Each SNP receives a weight based on the size of its effect in the GWAS — SNPs more strongly linked to the disease get larger weights.
3. When an individual's DNA is analyzed, the system counts how many risk alleles they carry, multiplies each by its SNP weight, and sums them all.
4. The result is a single number, usually compared against the population distribution and reported as a percentile — for example, being in the top 10% of scores.

The key point is that a PRS does not look for one "broken gene." It captures the combined influence of many genetic variants spread across the genome. That makes it fundamentally different from a targeted mutation test such as BRCA1/BRCA2, which provides a very different kind of information (see more on genetic cancer risk).

What Is a PRS Actually Useful For?

It is no crystal ball, but a PRS has genuine, valuable roles in modern medicine.

1. Stratifying risk to plan screening

For some conditions such as breast cancer and coronary heart disease, research suggests that people with a very high PRS (the top percentiles) may carry risk comparable to those with a clear family history. This can help clinicians consider starting screening (for example, mammography) earlier or more frequently in higher-risk individuals.

2. Adding to existing risk factors

A PRS provides information that is largely independent of traditional risk factors like age, blood pressure, cholesterol, or smoking. Combined with existing risk models, it can modestly improve accuracy in some contexts.

3. Motivating preventive behavior change

For many people, seeing a risk number is a powerful motivator to adjust diet, exercise, and regular check-ups. Crucially, most of the genetic influence a PRS captures is not an unchangeable fate — behavior still plays an enormous role in the final outcome.

A PRS is also a separate matter from ancestry analysis, which examines our ancestral makeup (see ancestry DNA analysis). Both read SNP data, but they answer entirely different questions.

Important Limitations: What a PRS Cannot Tell You

This section matters most, and I want everyone to read it fully before interpreting their own score.

Probabilistic, not diagnostic

A PRS only indicates a statistical tendency. Many people with high scores never develop the disease, and people with low scores still can, because environment, diet, smoking, and chance all contribute. A high score is therefore not a diagnosis and should not drive drastic medical decisions on its own.

Population bias

This is the biggest technical limitation. Most GWAS data used to build PRS models (historically over 80%) come from people of European ancestry. When a PRS developed on that data is applied to Asian, African, or other populations, accuracy drops significantly because SNP linkage patterns (linkage disequilibrium) and allele frequencies differ between populations. This is exactly why people in Thailand should interpret a PRS with extra caution and treat it as supporting information, not a final answer.

Only "common" variants are captured

A PRS aggregates common genetic variants found across the population, but it does not capture rare high-impact mutations or other influences such as epigenetics and gene-environment interactions. So a "normal" score does not guarantee freedom from every kind of genetic risk.

No single standard

Different labs and companies may use different SNP sets, weights, and reference populations, so a PRS for the "same disease" can give different results. Comparing across providers requires caution — much like single-gene testing such as the MTHFR gene, where interpretation always depends on clinical context. I always advise consulting a doctor or genetics specialist before making any decision based on these scores.

References

1. National Human Genome Research Institute (NHGRI). Polygenic Risk Scores. genome.gov
2. Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nature Reviews Genetics. 2018. nature.com
3. Martin AR, et al. Clinical use of current polygenic risk scores may exacerbate health disparities. Nature Genetics. 2019. nature.com
4. Lewis CM, Vassos E. Polygenic risk scores: from research tools to clinical instruments. Genome Medicine. 2020. genomemedicine.biomedcentral.com